...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurological sciences (Turkish) >Combination Treatment of Atorvastatin and Fasudil Ameliorate Cerebral Vasospasm after Subarachnoid Hemorrhage
【24h】

Combination Treatment of Atorvastatin and Fasudil Ameliorate Cerebral Vasospasm after Subarachnoid Hemorrhage

机译：蛛网膜下腔出血后阿托伐他汀联合法舒地尔改善脑血管痉挛的综合治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Cerebral vasospasm (CV) and early brain injury remain major causes of morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). The aims of this study were to investigate whether combination treatment, with atorvastatin as an inhibitor of RhoA and fasudil as an inhibitor of Rho-kinase, prevents the CV.Methods: Atovastatin, fasudil, or combination treatment were administrated. Ischemic lesion size was measured using computed tomography on the last available scan. Angiographic narrowing was semiquantitatively assessed in patients with vasospasm. The primary end point was the occurrence of cerebral infarction or symptomatic vasospasm (SV) caused by CV. The secondary end point was clinical outcome 6 months later.Results: In the trial population, cerebral infarction（20.5% vs.27.5% vs.29.3%） and SV（20.5% vs.26.8% vs. 27.5%） were significantly lower in the combination treatment group than in fasudil and atovastatin groups (both P0.05), mRS (P=0.06), and GOS (P>0.05) at 6 months. In the overall population, patients with SV had poorer clinical outcomes (P=0.05).Conclusion: Combination treatment reduces the incidence, severity and the ischemic consequences of vasospasm. Although no improvement of clinical outcome was seen in the combination population, there was a tendency for a better clinical outcome.
机译：目的：脑血管痉挛（CV）和早期脑损伤仍然是动脉瘤性蛛网膜下腔出血（SAH）后发病和死亡的主要原因。这项研究的目的是研究用阿托伐他汀作为RhoA抑制剂和法舒地尔作为Rho激酶抑制剂的联合治疗能否预防CV。方法：阿托伐他汀，法舒地尔或联合治疗。在最后一次可用的扫描中，使用计算机断层摄影术测量缺血性病变的大小。对血管痉挛患者的血管造影狭窄进行了半定量评估。主要终点是CV引起的脑梗塞或症状性血管痉挛（SV）的发生。次要终点是6个月后的临床结局。结果：在试验人群中，脑梗死（20.5％，27.5％，29.3％）和SV（20.5％，26.8％，26.8％和27.5％）。在6个月时，联合治疗组的百分率显着低于法舒地尔和阿托伐他汀组（均P0.05），mRS（P = 0.06）和GOS（P> 0.05）。在总体人群中，SV患者的临床结局较差（P = 0.05）。结论：联合治疗可降低血管痉挛的发生率，严重程度和缺血性后果。尽管在合并人群中未观察到临床结局的改善，但仍存在更好的临床结局的趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号